COL9A1
Collagen alpha-1(IX) chain
Also known as: CO9A1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P20849
- Gene
- COL9A1
- Ensembl
- ENSG00000112280
- Chromosome
- 6
- Canonical length
- 921 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted secreted proteins
- Secretome location
- Secreted to extracellular matrix
OverviewNCBI Gene
This gene encodes one of the three alpha chains of type IX collagen, which is a minor (5-20%) collagen component of hyaline cartilage. Type IX collagen is usually found in tissues containing type II collagen, a fibrillar collagen. Studies in knockout mice have shown that synthesis of the alpha 1 chain is essential for assembly of type IX collagen molecules, a heterotrimeric molecule, and that lack of type IX collagen is associated with early onset osteoarthritis. Mutations in this gene are associated with osteoarthritis in humans, with multiple epiphyseal dysplasia, 6, a form of chondrodysplasia, and with Stickler syndrome, a disease characterized by ophthalmic, orofacial, articular, and auditory defects. Two transcript variants that encode different isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
921 residues, UniProt reviewed canonical sequence.
>P20849|COL9A1
1 MKTCWKIPVF FFVCSFLEPW ASAAVKRRPR FPVNSNSNGG NELCPKIRIG QDDLPGFDLI
61 SQFQVDKAAS RRAIQRVVGS ATLQVAYKLG NNVDFRIPTR NLYPSGLPEE YSFLTTFRMT
121 GSTLKKNWNI WQIQDSSGKE QVGIKINGQT QSVVFSYKGL DGSLQTAAFS NLSSLFDSQW
181 HKIMIGVERS SATLFVDCNR IESLPIKPRG PIDIDGFAVL GKLADNPQVS VPFELQWMLI
241 HCDPLRPRRE TCHELPARIT PSQTTDERGP PGEQGPPGPP GPPGVPGIDG IDGDRGPKGP
301 PGPPGPAGEP GKPGAPGKPG TPGADGLTGP DGSPGSIGSK GQKGEPGVPG SRGFPGRGIP
361 GPPGPPGTAG LPGELGRVGP VGDPGRRGPP GPPGPPGPRG TIGFHDGDPL CPNACPPGRS
421 GYPGLPGMRG HKGAKGEIGE PGRQGHKGEE GDQGELGEVG AQGPPGAQGL RGITGIVGDK
481 GEKGARGLDG EPGPQGLPGA PGDQGQRGPP GEAGPKGDRG AEGARGIPGL PGPKGDTGLP
541 GVDGRDGIPG MPGTKGEPGK PGPPGDAGLQ GLPGVPGIPG AKGVAGEKGS TGAPGKPGQM
601 GNSGKPGQQG PPGEVGPRGP QGLPGSRGEL GPVGSPGLPG KLGSLGSPGL PGLPGPPGLP
661 GMKGDRGVVG EPGPKGEQGA SGEEGEAGER GELGDIGLPG PKGSAGNPGE PGLRGPEGSR
721 GLPGVEGPRG PPGPRGVQGE QGATGLPGVQ GPPGRAPTDQ HIKQVCMRVI QEHFAEMAAS
781 LKRPDSGATG LPGRPGPPGP PGPPGENGFP GQMGIRGLPG IKGPPGALGL RGPKGDLGEK
841 GERGPPGRGP NGLPGAIGLP GDPGPASYGR NGRDGERGPP GVAGIPGVPG PPGPPGLPGF
901 CEPASCTMQA GQRAFNKGPD PLocalizationUniProt · AlphaFold · HPA
Whether an antibody against COL9A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- choroid plexus: 24 nTPM
- prostate: 11 nTPM
- midbrain: 10 nTPM
- hypothalamus: 9.9 nTPM
- hippocampal formation: 9.4 nTPM
- amygdala: 9.3 nTPM
Single-cell type
- choroid plexus epithelial cells: 502 nCPM
- oligodendrocyte progenitor cells: 340 nCPM
- müller glia: 91 nCPM
- oligodendrocytes: 47 nCPM
- early spermatids: 40 nCPM
- pituitary stem cells: 38 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 91 nTPM
- medulla oblongata: 5.7 nTPM
- white matter: 4.4 nTPM
- pons: 4.1 nTPM
- midbrain: 3.8 nTPM
- hippocampal formation: 3.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about COL9A1.
Disease | AllUniProt
Conditions COL9A1 is implicated in, by any mechanism.
- Multiple epiphyseal dysplasia 6 (EDM6) MIM:614135
- Stickler syndrome 4 (STL4) MIM:614134
Disease | GeneticClinVar
101 pathogenic / likely-pathogenic of 1,497 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- COL9A1-related disorder
- Stickler syndrome, type 4
- See cases
- Connective tissue disorder
- Epiphyseal dysplasia, multiple, 6
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.81
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.19
- DepMap mean gene effect
- 0
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- carbohydrate binding
- extracellular matrix structural constituent conferring tensile strength
- metal ion binding
- protein homodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads COL9A1 as an antibody target. Whether an autoantibody or antibody against COL9A1 could matter depends on whether native COL9A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
COL9A1 is annotated as secreted, so native COL9A1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label COL9A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...